Ann: PAA completes Phase 1 and files for Orphan Drug Designation, page-395

It's not what PAA "Could" sell for it's what Big Pharma will 'Pay for"

In some cases BP will slice off a specific Treatment , especially if the Company has Empirical Evidence from Clinical Trials... which Possibly PAA will have , especially if the Principal Investigators put their Names and Qualifications alongside MPL's Mechanism of Action.

But in many cases BP want the lot ,,, if you don't work with BP then BP will work against you ,, that's how the machine works..

If you ask too much of a premium they just buy on market , they only need half the company to control it ,,, regrettably BP Dominate the Landscape ,,

Yes many are correct that MPL as Treatment could possess the ability to treat multiple Neurodegenerative diseases , each Disease would need a specific tailored trial and cost $10m / $20m ... to bring to market ,,, but PAA does not have the ability to < Manufacture, Sell, Distribute , Administration, after sales care ,warehousing or the contacts to commercialise MPL... for instance Pfizer who supply 129 Governments their drugs and services with 83,000 staff... and believe me if Pfizer could cut that number they would..

You have to understand eg Pfizer care about one thing " A solid return for their Investors" it's all about Money,,, that's why they don't push for Cures,, they push for Ongoing Treatments...such as MPL...

Hate to burst peoples bubble but it isn't Lollipops and Unicorns out there dancing over Rainbows,,, it's all about market face supply.... Govt and Health Insurer Supply...

If you wish to believe in the good side then the only benefit is BP want to milk the cow so will supply MPL to every single possible paying customer on the planet.... key term "Paying" NZT

PAA certainly has a Tiger by the Tail ,,,, but Big Pharma have the cages ,,, that's why the only defense is a higher SP and that is delivered through Demand and you require awareness to deliver Demand... Effective Market Messaging of Positive Results

Big Pharma have an industry standard for premiums ,,, here are 10
https://www.fiercepharma.com/pharma/top-10-ma-deals-2022

My rule of thumb 100% to 400% , 400% would be for a Baby Pharma with Revenue...